Autres langues Exelixis, Inc.

Actions

EXEL

US30161Q1040

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 15/07/2024			Varia. 5j.	Varia. 1 janv.
22,55 ^USD	+0,67 %		+2,08 %	-6,00 %

02/07	Ipsen élargit son partenariat avec Exelixis pour Cabometyx	MT
02/07	Ipsen : extension de la collaboration avec Exelixis	CF

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU : Citigroup, Constellation Brands, Broadcom, JPMorgan, Bunzl...	04/07
ANALYST RECOMMENDATIONS : Citigroup, Constellation Brands, Broadcom, JPMorgan, Bunzl...	04/07
Ipsen Expands Partnership with Exelixis for Cabometyx	02/07
Ipsen : extension de la collaboration avec Exelixis	02/07
Exelixis, Inc.(NasdaqGS:EXEL) added to Russell 1000 Defensive Index	01/07
Exelixis, Inc.(NasdaqGS:EXEL) added to Russell 1000 Value-Defensive Index	01/07
Exelixis, Inc.(NasdaqGS:EXEL) added to Russell 1000 Growth-Defensive Index	01/07
Exelixis Insider Bought Shares Worth $8,733,955, According to a Recent SEC Filing	31/05
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference	28/05
Exelixis Settles Cabometyx Patent Litigation with Cipla	20/05
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA	20/05
Exelixis Files Patent Complaint Against Cipla's Cancer Treatment	10/05
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May	07/05
Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Maintained -- Shares Fall After Hours	30/04
Exelixis Guides For 2024 Revenue of $1.825-$1.925 Billion, vs CIQ Analyst Consensus of $1.91 Billion	30/04
Earnings Flash (EXEL) EXELIXIS Reports Q1 Revenue $425.2M, vs. Street Est of $460.5M	30/04
Earnings Flash (EXEL) EXELIXIS Reports Q1 EPS $0.17, vs. Street Est of $0.29	30/04
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on January 8, 2024.	30/04
Exelixis: Q1 Earnings Snapshot	30/04
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update	30/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Exelixis, Inc.

Actions

EXEL

US30161Q1040

Autres langues

Filtres